VYC-17.5L effective, safe for nasolabial folds
VYC-17.5L (17.5 mg/mL hyaluronic acid, 0.3 percent lidocaine) has a good 1-year safety and effectivity profile for the treatment of moderate and severe nasolabial folds (NLF), a new study reveals.
The 70 participants (mean age 49±10 years; 94 percent female) with NLFs showed significant improvement in the primary endpoint of NLF severity in the left (mean change, -0.8± 0.8) and right (mean change, -0.8±0.7) NLFs at 12 months compared with baseline (p<0.0001).
Improvements in left and right NLF severity were also significant after the final treatment (mean changes, -2.0 and -1.9, respectively), after 1 month (mean change, -1.7 and -1.8, respectively) and after 9 months (mean change, -1.3 and -1.2, respectively; p<0.001 for all).
Mean investigator satisfaction scores ranged from 4.0±1.0 to 4.6±0.6 out of a maximum of 5 scores, while patient confidence scores were significantly higher after treatment compared with baseline.
Majority (n=67; 82.1 percent) of the patients were able to return to normal daily activity within 24 hours; four reported requiring recovery of 4 to 8 days before returning to normal activity.
Out of a maximum pain rating of 10, mean ratings were 2.0±1.8 for either side immediately after treatment. Pain ratings decreased to 0.7±1.5 and 0.8±1.7 for the left and right sides, respectively, after 14 days.
Initial swelling scores were 1.7±1.6 for either side and decreased to 1.4±2.2 and 1.5±2.2 for the left and right sides, respectively, at day 14. Bruising scores were initially 0.3±0.9 for both sides; ratings increased to 0.5±1.3 and 0.9±1.9 for left and right sides, respectively, after 14 days.
Only two adverse events were reported: reduced sensitivity, swelling and redness around the mouth (n=1), and swelling in the injection area (n=1). Both symptoms were resolved.